<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>25727830</identifier>
<setSpec>1668-3501</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Attie, Myriam</dc:author>
<dc:author>Rapetti, María Cristina</dc:author>
<dc:author>Crisp, Renée Leonor</dc:author>
<dc:author>García, Eliana</dc:author>
<dc:author>Donato, Hugo</dc:author>
<dc:description xml:lang="en">Hereditary spherocytosis must always be suspected in children with anemia, hyperbilirubinemia, splenomegaly or cholelithiasis, in the asymptomatic individual with an affected relative, and in the neonate with hyperbilirubinemia with no blood group incompatibility; its early detection is key to avoid kernicterus. Follow-up of these patients is based on periodical control and supply of information on the adequate management of hemolytic or aplastic crisis, and early detection of cholelithiasis. The decision to perform splenectomy is usually associated with quality of life rather than life-threatening risk, and it should result from a consensus between patient, parents and physicians. The postsplenectomy follow-up is based on control of compliance with the prophylactic antibiotic therapy and the early diagnosis of infectious disorders.</dc:description>
<dc:type>Journal Article</dc:type>
<dc:language>es</dc:language>
<dc:date>2015 Apr </dc:date>
<dc:title xml:lang="es">Esferocitosis hereditaria. Revisión. Parte II. Manifestaciones clínicas, evolución, complicaciones y tratamiento.</dc:title>
<dc:title xml:lang="en">[Hereditary spherocytosis. Review. Part II. Symptomatology, outcome, complications, and treatment].</dc:title>
<dc:publisher>Archivos argentinos de pediatria</dc:publisher>
</metadata>
</record>
</pubmed-document>
